| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
Revenue  | 952 | 778 | 800 | 811 | 1,223 | 1,029 | 989 | 1,086 | 974 | 986 | 1,025 | 1,098 | 1,242 | 1,193 | 1,564 | 1,585 | 1,557 | 1,483 | 1,673 | 1,784 | 1,621 | 1,712 | 1,765 | 1,885 | 2,060 | 1,808 | 1,945 | 2,223 | 2,476 | 2,217 | 2,384 | 3,020 | 3,929 | 3,516 | 3,551 | 4,135 | 3,912 | 4,543 | 3,604 | 3,826 | 4,415 |
| Expenses | 653 | 606 | 727 | 615 | 740 | 719 | 706 | 762 | 738 | 735 | 786 | 836 | 937 | 886 | 982 | 1,160 | 1,137 | 1,029 | 1,174 | 1,307 | 1,247 | 1,284 | 1,363 | 1,459 | 1,476 | 1,427 | 1,515 | 1,733 | 1,911 | 1,783 | 1,894 | 2,624 | 2,820 | 2,741 | 2,769 | 3,051 | 3,013 | 2,813 | 2,905 | 3,070 | 3,339 |
| EBITDA | 300 | 172 | 73 | 196 | 483 | 309 | 283 | 324 | 236 | 250 | 239 | 262 | 306 | 307 | 582 | 425 | 420 | 454 | 499 | 477 | 373 | 428 | 402 | 427 | 584 | 380 | 430 | 489 | 565 | 434 | 490 | 396 | 1,109 | 775 | 782 | 1,084 | 900 | 1,730 | 699 | 756 | 1,077 |
| Operating Profit % | 21 % | 20 % | 6 % | 22 % | 21 % | 27 % | 25 % | 27 % | 20 % | 21 % | 19 % | 21 % | 20 % | 21 % | 26 % | 25 % | 26 % | 29 % | 25 % | 25 % | 20 % | 24 % | 22 % | 21 % | 20 % | 19 % | 18 % | 20 % | 21 % | 17 % | 18 % | 11 % | 25 % | 20 % | 18 % | 14 % | 22 % | 17 % | 18 % | 19 % | 23 % |
| Depreciation | 59 | 59 | 61 | 64 | 65 | 66 | 68 | 70 | 73 | 99 | 94 | 97 | 95 | 99 | 112 | 117 | 120 | 124 | 132 | 144 | 152 | 167 | 178 | 186 | 184 | 195 | 202 | 206 | 212 | 218 | 231 | 301 | 364 | 358 | 389 | 415 | 407 | 405 | 420 | 425 | 436 |
| Interest | 0 | 4 | 3 | 2 | 21 | 6 | 7 | 9 | 5 | 16 | 14 | 15 | 17 | 18 | 19 | 19 | 16 | 17 | 14 | 18 | 17 | 13 | 7 | 5 | 34 | 20 | 23 | 15 | 11 | 20 | 30 | 120 | 249 | 233 | 248 | 267 | 227 | 236 | 226 | 223 | 212 |
| Profit Before Tax | 249 | 165 | 20 | 141 | 409 | 238 | 208 | 245 | 159 | 135 | 132 | 150 | 193 | 190 | 451 | 289 | 284 | 313 | 354 | 315 | 204 | 249 | 218 | 236 | 366 | 166 | 206 | 269 | 343 | 197 | 229 | -26 | 497 | 184 | 214 | 808 | 319 | 1,146 | 98 | 156 | 487 |
| Tax | 32 | 34 | 18 | 19 | 55 | 55 | 42 | 54 | 10 | 38 | 43 | 36 | 41 | 52 | 73 | 46 | 41 | 85 | 100 | 85 | 45 | 81 | 22 | 49 | 69 | 57 | 46 | 49 | 59 | 30 | 147 | -5 | 82 | 35 | 42 | 55 | 96 | 284 | 71 | 75 | 27 |
| Net Profit | 217 | 131 | 2 | 122 | 354 | 182 | 167 | 191 | 148 | 98 | 89 | 114 | 153 | 138 | 378 | 243 | 243 | 228 | 254 | 230 | 159 | 168 | 195 | 187 | 296 | 108 | 160 | 220 | 284 | 167 | 82 | -21 | 415 | 149 | 173 | 753 | 223 | 862 | 27 | 81 | 459 |
| EPS in ₹ | 10.08 | 6.31 | -0.54 | 5.30 | 16.97 | 8.49 | 7.48 | 8.72 | 6.49 | 1.38 | 1.17 | 1.56 | 2.21 | 1.02 | 3.00 | 3.67 | 3.61 | 1.74 | 1.82 | 1.71 | 1.04 | 1.26 | 1.39 | 1.42 | 2.13 | 0.71 | 1.16 | 1.57 | 2.00 | 1.21 | 0.39 | -0.35 | 2.62 | 0.85 | 1.05 | 5.52 | 1.13 | 5.51 | -0.13 | 0.21 | 2.88 |
Biocon
342.00
-10.65
(-3.02%)
There are new updates from the company1 day ago
View
Market Cap
41,060.52 Cr
EPS
8.55
PE Ratio
45.03
Dividend Yield
0.35 %
Industry
Healthcare52 Week High
404.70
52 Week Low
291.00
PB Ratio
1.96
Debt to Equity
0.91
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from15 analysts
Company News
View All News
Biocon Ltd: Rs 4,500 Crore QIP to Provide Investor Exits, Closes Listing Window for Subsidiary1 day ago
Biocon Ltd is raising Rs 4,500 crore through a QIP to provide exits to private equity investors in its subsidiary, Biocon Biologics Ltd. This move closes the window for listing the subsidiary. The funds will be used to redeem OCDs issued to Goldman Sachs entities and pre-pay other financial commitments. Post-buyback, Biocon will hold 73.84% in Biocon Biologics.
Biocon opened its Qualified Institutions Placement (QIP) issue on June 16, 2025, with a floor price set at Rs 340.20 per equity share. The Fund Raising Committee approved the opening of the issue following board and shareholder approvals. The company will determine the final issue price in consultation with Book Running Lead Managers.
Biocon: Launches ₹4,500 Crore QIP with ₹340.20/Share Floor Price2 days ago
Biocon initiated a Qualified Institutional Placement (QIP) to raise ₹4,500 crore, setting a floor price of ₹340.20 per share. The company may offer up to a 5% discount on the floor price. Proceeds will be used to purchase outstanding debentures from its subsidiary Biocon Biologics and manage existing financial commitments.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,648.00 | #1 3,95,410.40 | 34.49 | #1 49,887.20 | 12.06 | #1 9,648 | -18.99 | 36.89 | |
6,549.00 | 1,73,855.37 | 79.21 | 8,184.00 | 0.89 | 1,600 | 23.05 | 52.65 | |
1,498.10 | 1,20,988.79 | 23.03 | 26,520.70 | 14.17 | 4,155 | 30.28 | 50.44 | |
1,313.30 | 1,09,589.02 | 19.46 | 28,905.40 | 12.36 | 5,578 | 21.14 | 61.31 | |
3,227.00 | 1,09,216.34 | 57.08 | 10,785.70 | 11.59 | 1,656 | 10.91 | 51.94 | |
2,358.30 | 97,298.39 | 48.87 | 10,615.60 | 19.57 | 1,942 | -10.91 | 40.24 | |
958.30 | 96,427.40 | 20.66 | 19,831.50 | 13.82 | 3,831 | -0.19 | 60.33 | |
1,954.00 | 89,208.10 | 27.04 | 20,141.50 | #1 19.94 | 1,936 | #1 112.49 | 43.06 | |
31,565.00 | 67,073.42 | 47.78 | 6,097.20 | 10.80 | 1,201 | 27.83 | 58.17 | |
1,105.30 | 64,196.00 | #1 18.65 | 29,559.20 | 17.55 | 3,169 | -0.50 | 35.01 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
35.25 %
Net Income Growth
101.84 %
Cash Flow Change
59.45 %
ROE
79.37 %
ROCE
103.31 %
EBITDA Margin (Avg.)
6.64 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 6,375 | 8,458 | 9,394 | 9,990 | 12,192 | 14,444 | 18,522 | 20,394 | 52,043 | 56,071 |
| Fixed Assets | 1,630 | 1,749 | 3,626 | 3,700 | 4,471 | 5,971 | 6,364 | 6,569 | 29,468 | 30,644 |
| Current Assets | 2,563 | 3,971 | 4,048 | 4,149 | 4,889 | 5,325 | 7,600 | 8,382 | 12,334 | 15,179 |
| Capital Work in Progress | 1,677 | 2,240 | 839 | 1,303 | 1,899 | 2,196 | 2,800 | 4,110 | 7,317 | 7,993 |
| Investments | 230 | 901 | 1,253 | 675 | 1,012 | 966 | 1,952 | 1,588 | 2,069 | 1,000 |
| Other Assets | 2,839 | 3,569 | 3,676 | 4,312 | 4,811 | 5,311 | 7,406 | 8,127 | 13,189 | 16,434 |
| Total Liabilities | 6,375 | 8,458 | 9,394 | 9,990 | 12,192 | 14,444 | 18,522 | 20,394 | 52,043 | 56,071 |
| Current Liabilities | 1,555 | 1,666 | 1,678 | 2,141 | 3,039 | 4,008 | 4,210 | 3,828 | 8,511 | 15,359 |
| Non Current Liabilities | 1,378 | 2,493 | 2,502 | 2,200 | 2,447 | 3,053 | 5,805 | 7,096 | 21,043 | 15,437 |
| Total Equity | 3,443 | 4,300 | 5,214 | 5,649 | 6,707 | 7,383 | 8,508 | 9,470 | 22,489 | 25,275 |
| Reserve & Surplus | 3,171 | 3,992 | 4,738 | 4,881 | 5,798 | 6,106 | 7,027 | 7,832 | 17,267 | 19,183 |
| Share Capital | 100 | 100 | 100 | 300 | 300 | 600 | 600 | 600 | 600 | 600 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | -94 | 300 | -47 | -261 | 210 | 165 | 72 | -243 | 641 | -380 |
| Investing Activities | -491 | -1,138 | -510 | -684 | -703 | -1,505 | -3,651 | -1,662 | -14,260 | -1,002 |
| Operating Activities | 211 | 371 | 640 | 662 | 1,155 | 1,283 | 1,160 | 1,177 | 1,853 | 2,954 |
| Financing Activities | 186 | 1,068 | -178 | -240 | -242 | 388 | 2,564 | 242 | 13,049 | -2,333 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
| Promoter | 60.67 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 7.96 % | 6.55 % | 5.63 % | 5.90 % | 5.93 % | 5.66 % | 5.66 % |
| DIIs | 6.65 % | 6.89 % | 6.87 % | 6.83 % | 7.79 % | 7.30 % | 7.76 % | 8.63 % | 11.90 % | 12.56 % | 14.08 % | 14.51 % | 13.68 % | 14.30 % | 14.44 % | 15.37 % | 15.72 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 10.89 % | 11.03 % | 11.49 % | 11.37 % | 10.87 % | 10.72 % | 12.07 % | 12.46 % | 13.21 % | 13.34 % | 13.61 % | 14.47 % | 15.53 % | 14.63 % | 14.57 % | 14.07 % | 13.63 % |
| Others | 21.79 % | 21.44 % | 21.00 % | 21.16 % | 20.70 % | 21.35 % | 19.54 % | 18.27 % | 14.26 % | 13.46 % | 3.70 % | 3.83 % | 4.52 % | 4.53 % | 4.42 % | 4.27 % | 4.34 % |
| No of Share Holders | 0 | 3,11,349 | 3,38,815 | 3,63,447 | 3,64,502 | 3,47,911 | 3,41,016 | 3,69,816 | 4,11,086 | 4,12,441 | 4,15,046 | 4,34,339 | 4,70,261 | 4,43,513 | 4,39,503 | 4,27,705 | 4,24,297 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 3 | 1 | 1 | 0.00 | 0.00 | 0.5 | 1.5 | 0.5 | 0.00 |
| Dividend Yield (%) | 0.00 | 1.01 | 0.33 | 0.37 | 0.00 | 0.00 | 0.25 | 0.57 | 0.15 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 08 Aug 2025 |  Annual General Meeting | NA | 08 Aug 2025 | 346.50 | 352.55 |
| 04 Jul 2025 |  Dividend | ₹ 0.50 /share | 04 Jul 2025 | 346.50 | 352.55 |
| 08 May 2025 |  Quarterly Result Announcement | NA | 08 May 2025 | 339.10 | 346.50 |
| 30 Jan 2025 | Quarterly Result Announcement | NA | 30 Jan 2025 | 372.95 | 355.70 |
| 30 Oct 2024 | Quarterly Result Announcement | NA | 30 Oct 2024 | 370.65 | 326.85 |
| 09 Aug 2024 | Annual General Meeting | NA | 09 Aug 2024 | 311.90 | 339.20 |
| 05 Jul 2024 | Dividend | ₹ 0.50 /share | 05 Jul 2024 | 311.90 | 361.10 |
| 07 Jul 2023 | Dividend | ₹ 1.50 /share | 07 Jul 2023 | 240.45 | 259.50 |
| 01 Jul 2022 | Dividend | ₹ 0.50 /share | 30 Jun 2022 | 382.30 | 308.40 |
| 13 Jun 2019 |  Bonus | 1:1 | 12 Jun 2019 | 271.45 | 257.90 |
Announcements
Credit Rating
1 day ago
1 day agoQualified Institutions Placement Of Equity Shares2 days ago
2 days agoIntimation Of The Approval Of The Audited Consolidated Financial Statements For The Financial Year March 31 20252 days ago
2 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release9 days ago
9 days agoShareholder Meeting / Postal Ballot-Outcome of Postal_BallotJun 04, 2025
Jun 04, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJun 04, 2025
Jun 04, 2025Press ReleaseJun 02, 2025
Jun 02, 2025Reminder Letter To Holders Of Physical Securities For Furnishing Of KYC DetailsMay 27, 2025
May 27, 2025Company StatementMay 25, 2025
May 25, 2025Company StatementMay 22, 2025
May 22, 2025Company StatementMay 21, 2025
May 21, 2025Transcript Of Earnings Call Q4 FY25May 15, 2025
May 15, 2025Notification To Stock ExchangeMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 14, 2025
May 14, 2025Reminder Letter To Shareholders To Claim Unclaimed DividendsMay 13, 2025
May 13, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 12, 2025
May 12, 2025Investor PresentationMay 12, 2025
May 12, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 10, 2025
May 10, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 09, 2025
May 09, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 09, 2025
May 09, 2025Fixation Of Record Date For DividendMay 08, 2025
May 08, 2025Corporate Action-Board approves DividendMay 08, 2025
May 08, 2025Board Meeting Outcome for Financial Results For Quarter And Year Ended March 31 2025May 08, 2025
May 08, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 08, 2025
May 08, 2025Financial Results For The Quarter And Year Ended March 31 2025May 08, 2025
May 08, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 06, 2025
May 06, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotMay 05, 2025
May 05, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 05, 2025
May 05, 2025Intimation Of Record Date For Commercial PapersApr 30, 2025
Apr 30, 2025Redemption Of Commercial PapersApr 29, 2025
Apr 29, 2025 Company Statement Dated April 26 2025Apr 26, 2025
Apr 26, 2025Board Meeting Outcome for Outcome Of Board MeetingApr 23, 2025
Apr 23, 2025Issue Of Commercial PapersApr 22, 2025
Apr 22, 2025Board Meeting Intimation for To Consider And Approve The Proposal For Raising Of Funds.Apr 20, 2025
Apr 20, 2025Announcement under Regulation 30 (LODR)-Credit RatingApr 15, 2025
Apr 15, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 15, 2025
Apr 15, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 14, 2025
Apr 14, 2025Notification To Stock ExchangesApr 10, 2025
Apr 10, 2025Certificate Pursuant To SEBI Master Circular No. SEBI/HO/DDHS/Pod1/P/CIR/2024/54
Dated May 22 2024.Apr 10, 2025
Apr 10, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 10, 2025
Apr 10, 2025Board Meeting Outcome for Outcome Of Board Meeting - Disclosure Under Reg 30Apr 04, 2025
Apr 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 02, 2025
Apr 02, 2025Board Meeting Intimation for Board Meeting IntimationApr 02, 2025
Apr 02, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportApr 02, 2025
Apr 02, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotApr 02, 2025
Apr 02, 2025Announcement under Regulation 30 (LODR)-CessationApr 01, 2025
Apr 01, 2025Board Meeting Intimation for Intimation For The Board Meeting Pursuant To Regulation 29(1)(D) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 - Raising Of FundsApr 01, 2025
Apr 01, 2025Announcement Under Regulation 30Mar 29, 2025
Mar 29, 2025Reminder Letter To Shareholders For Claiming Unclaimed Dividend And Updation Of KYC InformationMar 28, 2025
Mar 28, 2025Closure of Trading WindowMar 28, 2025
Mar 28, 2025Technical Indicators
RSI(14)
Neutral 51.04
ATR(14)
Volatile 10.09
STOCH(9,6)
Neutral 78.13
STOCH RSI(14)
Neutral 65.95
MACD(12,26)
Bullish 1.10
ADX(14)
Weak Trend 15.28
UO(9)
Bearish 52.51
ROC(12)
Uptrend But Slowing Down 2.40
WillR(14)
Neutral -61.13
Mutual Fund Holdings
Invesco India Arbitrage Fund Direct-Growth 
Bajaj Finserv Large and Mid Cap Fund Direct-Growth 
Kotak Equity Arbitrage Fund Direct-Growth 
Nippon India Flexi Cap Fund Direct - Growth 
Tata Arbitrage Fund Direct - Growth 
SBI Arbitrage Opportunities Fund Direct-Growth 
DSP Dynamic Asset Allocation Fund Direct-Growth 
HDFC Arbitrage Fund Wholesale Direct-Growth 
Edelweiss Arbitrage Fund Direct-Growth 
Bandhan Multi Cap Fund Direct-Growth 
ICICI Prudential Equity Arbitrage Direct-Growth 
UTI Arbitrage Fund Direct-Growth 
HSBC Arbitrage Fund Direct-Growth 
Axis Arbitrage Fund Direct-Growth 
LIC MF Flexi Cap Fund Direct-Growth 
Aditya Birla Sun Life Arbitrage Fund Direct-Growth 
JM Arbitrage Fund Direct-Growth About Biocon
Biocon Limited is India's largest fully-integrated biopharmaceutical company, focusing on biotechnology products and research services. Founded in 1978, Biocon specializes in treating diabetes, cancer, and autoimmune diseases. The company develops and commercializes novel biologics, biosimilars, complex small molecule APIs, and generic formulations for global markets. Biocon's product portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, and oncology treatments. The company operates manufacturing facilities in Bangalore, Hyderabad, and Visakhapatnam, utilizing various technology platforms such as microbial fermentation, chromatographic purification, chemical synthesis, and peptide synthesis. Biocon has expanded its global presence through strategic partnerships and has launched several biosimilar and generic products in international markets, including the United States, Europe, and emerging economies.
Listing Date
07 Apr, 2004(21 Years,
12 days)
Website
Chairperson NameKiran Mazumdar Shaw
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
